Picture loading failed.

Pre-made Gontivimab benchmark antibody (Bispecific Single Domains (VH-VH'-VH'), anti-RSV gpF therapeutic antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Gontivimab is a monoclonal antibody-derived therapeutic protein (Nanobodies®) (designated as ALX 0171), being developed by Ablynx (a subsidiary of Sanofi) as a once-daily treatment of patients with respiratory syncytial virus (RSV) infections.

Order information

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-251-1mg 1mg Inquiry
GMP-Bios-ab-251-10mg 10mg Inquiry
GMP-Bios-ab-251-100mg 100mg Inquiry
GMP-Bios-ab-251-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Pre-Made Gontivimab biosimilar, Bispecific Single Domains (VH-VH'-VH’): Anti-RSV gpF therapeutic antibody
INN Name Gontivimab
TargetRSV gpF
FormatBispecific Single Domains (VH-VH'-VH')
DerivationBispecific antibody
Species ReactivityHuman
CH1 Isotypena
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI StructureNone;None
99% SI StructureNone;None
95-98% SI StructureNone;None
Year Proposed2019
Year Recommended2020
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedRespiratory syncytial virus infections
Development Techna